Why Is Apimeds Pharmaceuticals Stock Gaining Monday?

10/5/2026
Impact: 85
Healthcare

Apimeds Pharmaceuticals (AMEX: APUS) stock rose 43.48% to $4.62 following the announcement that its subsidiary, MindWave Innovations, signed a two-year agreement with BlockAssure Inc. to develop a blockchain network for insurance operations. The stock initially surged over 76% in premarket trading, with trading volume reaching 21.59 million shares, significantly higher than its 100-day average of 2.06 million shares. MindWave will receive development fees and a 20% allocation of a new digital token, AssureCoin, contingent on its launch.

AI summary, not financial advice

Share: